Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Lateral mesoderm-derived mesenchymal stem cells with robust osteochondrogenic potential and hematopoiesis supporting ability

ABSTRACT: Lateral mesoderm-derived mesenchymal stem cells with robust osteochondrogenic potential and hematopoiesis supporting ability

PROVIDER: PRJNA755197 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR15465955_1.fastq.gz	Fastqsanger.gz
	SRR15465955_2.fastq.gz	Fastqsanger.gz
	SRR15465956_1.fastq.gz	Fastqsanger.gz
	SRR15465956_2.fastq.gz	Fastqsanger.gz
	SRR15465957_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 12

Similar Datasets

Lateral mesoderm-derived mesenchymal stem cells with robust osteochondrogenic potential and hematopoiesis supporting ability

Project description:Here, hiPSCs were induced to differentiate to mesenchymal stem cells (MSCs) through the intermediate stage of lateral mesoderm (LM). We sequenced mRNA samples of LM and LM-MSCs to generate the gene expression profiles of these cells.

2022-01-19 | GSE182161 | GEO

Expression profiling of retinoic acid targets in lateral mesoderm from Xenopus laevis embryos

Project description:Renal precusors of the Xenopus pronephros arise from dorso-lateral mesoderm at the early neurula stage. This process is under the control of retinoic acid (RA). We have used microarrays to identify RA targets in dorso-latearl mesoderm by performing differential expression analysis between control and RA-depleted situations

2022-06-13 | GSE205827 | GEO

Development of the chicken lateral plate mesoderm and forelimb mesenchyme

Project description:Development of the chicken lateral plate mesoderm and forelimb mesenchyme

| PRJNA878680 | ENA

Development of the chicken lateral plate mesoderm and forelimb mesenchyme

Project description:The lateral plate mesoderm (LPM) is a transient tissue that produces a diverse range of differentiated structures, including the limbs. However, the molecular mechanisms that drive early LPM specification and development are poorly understood. In this study, we utilize single-cell transcriptomics to define the cell-fate decisions directing LPM specification, subdivision, and early initiation of the forelimb mesenchyme in chicken embryos. We establish a transcriptional atlas and global cell-cell signalling interactions in progenitor, transitional and mature cell types throughout the developing forelimb field.

2022-09-13 | GSE212985 | GEO

Expression profiling of retinoic acid targets in lateral mesoderm from Xenopus laevis embryos

Project description:Expression profiling of retinoic acid targets in lateral mesoderm from Xenopus laevis embryos

| PRJNA847903 | ENA

SETD7 promotes lateral plate mesoderm formation by modulating the Wnt/b-catenin signaling pathway

Project description:SETD7 promotes lateral plate mesoderm formation by modulating the Wnt/b-catenin signaling pathway

| PRJNA949202 | ENA

Human Mesenchymal Stem / Stromal Cells (hMSCs) treated with Eltrombopag show increase of the hematopoietic supporting ability

Project description:Human Mesenchymal Stem / Stromal Cells (hMSCs) treated with Eltrombopag show increase of the hematopoietic supporting ability

| PRJNA834765 | ENA

Human Mesenchymal Stem / Stromal Cells (hMSCs) treated with Eltrombopag show increase of the hematopoietic supporting ability

Project description:Eltrombopag (EP) is a small molecule that acts on hematopoietic cells and megakaryocytes to stimulate the hematopoiesis. Mesenchymal stem/stromal cells (MSCs) are key hematopoietic niche regulators. In the current work we aimed to assess if EP exert any effect on MSCs function, especially on their hematopoietic-supporting ability, and if so, what are the changes (including transcriptomic) induced in MSCs after EP treatment. For this purpose, MSCs were isolated from 12 healthy donors and treated with 15 uM and 50 uM of EP for 24 hours. The toxicity of the drug on MSCs and their differentiation ability were analyzed, as well as the transcriptomic profile, ROS and DNA damage and finally the changes induced in the clonogenic capacity of HSC. We observed that EP acts on MSCs decreasing their adipogenic differentiation, increasing the expression of genes involved in hypoxia and other pathways and enhancing their ability to support hematopoiesis. We used high density oligo microarrays (Affymetrix Clariom_S_Human) to obtain the global programme of gene expression underlying the effect of the Eltrombopag (EP) and Thrombopoietin (TPO) in human MSCs (derived from bone marrow) and identify the genes activity.

2023-01-07 | GSE202127 | GEO

scRNAseq datasets supporting a common precursor expression program leading to brain pericyte differentiation from neural crest and mesoderm

Project description:scRNAseq datasets supporting a common precursor expression program leading to brain pericyte differentiation from neural crest and mesoderm

| PRJNA971152 | ENA

Twist1-Haploinsufficiency Selectively Enhances the Osteoskeletal Capacity of Mesoderm-derived Parietal Bone through Downregulation of Fgf23

Project description:Purpose: This study investigates the postnatal impact of Twist1 haploinsufficiency on the osteoskeletal ability and regeneration on two calvarial bones arising from tissues of different embryonic origin: the neural crest-derived frontal and the mesoderm-derived parietal bones. Results: Twist1 haplonsufficiency selectively enhanced osteogenic and tissue regeneration ability of mesoderm-derived parietal bones. Twist1 haplonsufficiency triggers its selective activity on mesoderm-derived parietal bone through downregulation of the bone-derived hormone Fgf23. Conclusions: Twist1 haploinsufficiency preferentially triggers osteogenic induction of parietal bones which may be beneficial to optimize treatments for skeletal regeneration, reconstruction and repair of mesoderm-derived bone, as well as to alleviate skeletal abnormalities caused by Twist1 haploinsufficiency.

2018-09-15 | GSE119962 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data